{
    "type": "VariantTherapeuticResponseProposition",
    "predicate": "sensitivity",
    "description": "In combination with trametinib, for the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options",
    "geneContextQualifier": "BRAF",
    "objectTherapeutic": "Dabrafenib [Tafinlar]"
}